Edgewise Therapeutics (EWTX) Interest & Investment Income (2020 - 2026)

Edgewise Therapeutics has reported Interest & Investment Income for 7 years, with the latest figure at $5.1 million in Q1 2026.

• Quarterly Interest & Investment Income fell 1.14% year-over-year to $5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.6 million (down 1.67% YoY) and the FY2025 annual result came in at $23.6 million, down 5.63% from the prior year.
• Interest & Investment Income retreated to $5.1 million in Q1 2026 per EWTX's latest filing, from $5.8 million in the prior quarter.
• Over five years, Interest & Investment Income peaked at $6.6 million in Q2 2024 and troughed at $166000.0 in Q1 2022.
• A 5-year average of $4.2 million and a median of $5.1 million in 2026 frame the typical range for Interest & Investment Income.
• The sharpest annual moves came in 2022 and 2025: Interest & Investment Income jumped 2014.29% in 2022, then declined 17.13% in 2025.
• Over 5 years, Interest & Investment Income stood at $2.7 million in 2022, then jumped by 39.6% to $3.7 million in 2023, then jumped by 58.05% to $5.9 million in 2024, then decreased by 1.96% to $5.8 million in 2025, then slipped by 11.47% to $5.1 million in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $5.1 million, $5.8 million, and $6.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.